The Mark Foundation for Cancer Research US Ltd

Analysis

The Mark Foundation for Cancer Research US Ltd is a registered charity in United States, based in New York, NY. It received its IRS tax-exemption ruling in August 2016, 10 years ago. Its declared purposes cover diseases, disorders and medical disciplines, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, The Mark Foundation for Cancer Research US Ltd reported income of $40.9m and spending of $35.2m, spending 86% of its income. Across the 5 years on record, from December 2019 to December 2023, income fell from $80.5m to $40.9m (-49%), an average of -16% a year. The sharpest change came in the year to December 2020, when income dropped by 50%. Over the whole period it spent 70% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, The Mark Foundation for Cancer Research US Ltd sits at the 92nd percentile: it is larger than about 92% of them. Against every charity in United States with reported income it ranks in the 98th percentile, and in the 98th percentile within NY. Charities of a similar size with the same main cause include Bethesda ($40.9m), St Marys Medical Group Inc ($41.0m) and Vna Home & Hospice ($40.9m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 97% of the total. Compensation of current officers, directors and key employees was $1.8m (5.2% of expenses). Other salaries and wages came to $1.0m. At year end it held assets of $104.5m against liabilities of $20.0m, net assets of $84.5m. It reported 11 employees.